Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset ...

Citi initiated coverage of Cytokinetics (CYTK) with a Buy rating and $86 price target. The shares seem attractive at current levels, given the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report) and ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is ...

Citi initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and an $86.00 price target, representing significant upside from the current price of $46.17. The firm's analysts highlighted ...

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Cytokinetics announced that it has begun enrolling patients in its mid-stage study of CK-4021586 (CK-586), a ...

JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate of 64,587 shares of common stock, 41,939 restricted stock units ...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at ...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its seventh annual Communications Grant Program ...

Inspire Investing LLC boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.8% in the ...